Andres Gomez
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Andres Gomez
Apr 19, 2024, 06:41 |
Blog
Andres Gomez: The future of clinical research in Latin America is safe in the hands of these bright minds
Andres Gomez, Associate Professor at The Autonomous University of Nuevo León, Monterrey, Mexico shared on…
Feb 26, 2024, 17:54 |
Blog
Andres Gomez: Retrospective data continues to favor haploidentical in adults with Acute Lymphocytic Leukemia
Andres Gomez, Associate Professor at the Autonomous University of Nuevo León, recently posted on X/Twitter:…
Dec 12, 2023, 18:30 |
Blog
Andres Gomez: Learn about resource optimization in Low- and Middle-Income Countries with Héctor Vaquera
Andres Gomez, Associate Professor at The Autonomous University of Nuevo León, shared a post on…
Nov 20, 2023, 03:53 |
Insight
Andres Gomez: This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3
Andres Gomez, Associate Professor at the Autonomous University of Nuevo León, Monterrey, Mexico, posted on…
Sep 17, 2023, 16:54 |
Opinion
Andres Gomez: In my view, the most important issue for AML patients worldwide is lack of access to comprehensive testing.
Quoting Andres Gomez, Associate Professor at UANL Monterrey, Mexico, on X/Twitter: "I like the paper…
Aug 29, 2023, 19:15 |
Insight
Andres Gomez: Venetoclax can be effectively reduced to 100 mg when combined with azoles in a first-line, phase 2 trial done under limited resources.
Andres Gomez, an Associate Professor at Universidad Autónoma de Nuevo León, Mexico, recently tweeted: "Venetoclax…
All:
6
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube